advertisement
Abstract #8944 Published in IGR 5-2
Effect of changing from concomitant timolol pilocarpine to bimatoprost monotherapy on ocular blood flow and IOP in primary chronic angle closure glaucoma
Agarwal HC; Gupta V; Sihota RJournal of Ocular Pharmacology and Therapeutics 2003; 19: 105-112
The aim of the present prospective masked study was to assess the effect of bimatoprost monotherapy on ocular blood flow and intraocular pressure (IOP) in eyes of primary chronic angle-closure glaucoma (PCACG) patients already on concomitant timolol and pilocarpine. Thirty-two patients with bilateral PCACG on topical timolol 0.5% twice a day and pilocarpine 2% three times daily were switched over to bimatoprost 0.03% once daily in both eyes. IOP and pulsatile ocular blood flow (POBF) were recorded before and after starting bimatoprost and were followed up every four weeks for three months. Bimatoprost had a statistically significant (p < 0.05) mean IOP reduction from 19.3 ± 6.6 to 13.5 ± 4.5 mmHg (30.5%) and there was improvement of from 858 ± 260 to 1261 ± 321 μl/min (46.8%) in mean pulsatile ocular blood flow (p < 0.05). Conjunctival hyperemia (32%) was the most common adverse effect of bimatoprost. Bimatoprost 0.03% monotherapy improved ocular blood flow and provided a better diurnal IOP control than concomitant timolol-pilocarpine in eyes with PCACG and was found to be well tolerated.
Dr. H.C. Agarwal, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. gupta_v@mailcity.com
Classification:
11.2 Cholinergic drugs (Part of: 11 Medical treatment)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
